BDX's Principal Activity is the bCAL Diagnostics Limited is a biotechnology company developing a blood based diagnostic test for breast cancer.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-54.12%|
|ASX Rank||1,731 of 2,316|
|Sector Rank||167 of 198|
BCAL Diagnostics Limited (BDX) s a company focused on the development of a non-invasive blood based in vitro diagnostic (IVD) technology to detect breast cancer.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Mr Mark Douglas Irving Burrows||Non-Executive Director||Jul 2021||
Mr Mark Douglas Irving Burrows
Mr Burrows has experience in diagnosis of breast cancer and other cancers. He has career in investment banking both in Australia and the UK. Mark co-founded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/ Deputy Chairman of ING Barings in London. In 2004, Mark joined Lazard as a Managing Partner and in 2006 returned to Australia and was appointed Lazard Australia's inaugural Chairman. Mark returned to investment banking in 2011 as Vice Chairman of Credit Suisse's Global Investment Bank. During his investment banking career, Mark has been the principal financial advisor to some of the transformative corporate and government transactions in Australia. Mark has served as a non-executive director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra. Since the Rio Earth Summit in 1992, Mark has also been supporter of global financial institutions' Private Sector involvement in sustainable development. Over this period, Mark has retained a number of roles advising United Nations, G20 and corporates on climate initiatives relating to the financial sector. From 2017 to 2020, Mark was a Senior Advisor to Macquarie Bank, on climate finance and renewable energy. Mark currently retains a role as a senior advisor to UNEP, UNDP, The Green Finance Initiative in London and is on the Asian Council of The Nature Conservancy. He is also a Senior Advisor to the G20 Sustainability Group.
|Dr Merilyn Joy Sleigh||Non-Executive Director||Mar 2021||
Dr Merilyn Joy Sleigh
Dr Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia's biotechnology sector. She was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that expanded internationally and listed on the ASX before acquisition by a larger company. She was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. She has held non-executive director positions with Mimetica Pty Ltd and Adalta Ltd as well as with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd. Other director roles have been with government and not-for-profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia. She has acted as an adviser and consultant to companies, government, research institutes and investors on technology commercialization. She is also member of the Risk Management Committee of BDX.
|Mr Jonathan Alfred Grey Trollip||Non-Executive Director||Dec 2020||
Mr Jonathan Alfred Grey Trollip
Mr Trollip is an experienced Director with over 30 years of commercial, corporate, governance and legal and transactional experience. He is currently non-executive Chairman of ASX listed Global Value Fund Limited, Future Generation Investment Company Limited, Antipodes Global Investment Company Limited, Plato Income Maximser Limited, and Spheria Emerging Companies Limited and a non-executive director of ASX listed Propel Funeral Partners Limited and LSE listed Kore Potash PLC. He has experience in the not-for-profit sector. He is also chairman of the Risk Management Committee of BDX.
|Ms Jayne Andrea Shaw||Executive Chairman,Executive Director||Feb 2010||
Ms Jayne Andrea Shaw
Executive Chairman,Executive Director
Ms Shaw has become a Director of Nursing and Chief Executive Officer of two private hospitals in Australia after completion of her training in nursing. Following this, she established an Australian and international consulting business which was sold to Healthsouth, a USA Healthcare company. Jayne then became the Co-founder of Vision Group, an Ophthalmic Doctor equity consolidation model that was successfully listed on the ASX. Jayne joined a number of private healthcare boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women's Health, and continued to work with private equity firms on local and international healthcare transactions. Jayne, together with Ron Phillips, was a co-owner of Sydney Breast Clinic and a co-founder of BCAL. Current board positions are The Woolcock Research Institute, Corum Group (ASX: COO) and Mable Technologies.
|Hon Ronald (Ron) Anthony Phillips||Non-Executive Director||Feb 2010||
Hon Ronald (Ron) Anthony Phillips
The Hon Phillips has been worked for 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition. Ron has developed a consulting business in the Health and Aged Care Industry. His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He recently retired as Chair of the Sydney Local Health District and as Director of Westmead IVF. He is also member of the Risk Management Committee of BDX.
|Mr Guy Adrian Robertson||Chief Financial Officer,Company Secretary||N/A|
BDX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|07/09/21||Jayne Shaw||Buy||+20,000||$0.20||$4,002||On-market trade|
|06/09/21||Jayne Shaw||Buy||+180,000||$0.20||$36,000||On-market trade|
The current holdings of BDX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Ronald (Ron) Phillips||15/02/2010||8,102,858||18,411,709||2,022,638||N/A|
No Substantial Shareholders for BDX in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|21-07-21||Regal Funds Management Pty Limited||12,171,945||--||5.88|
|07-01-21||Mera Vale No 3 Pty Ltd||12,943,471||--||6.26|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.